2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100085R
    21-Desacetyldeflazacort (Standard) 13649-57-5
    21-Desacetyldeflazacort (Standard) is the analytical standard of 21-Desacetyldeflazacort. This product is intended for research and analytical applications. 21-Desacetyldeflazacort (21-desDFZ) is the active metabolite of Deflazacort (HY-13609). Deflazacort is an anti-inflammatory and immunosuppressant. Deflazacort is an inactive pro-drug which can be rapidly converted by esterases to the active metabolite 21-desacetyldeflazacort after oral administration.
    21-Desacetyldeflazacort (Standard)
  • HY-100113R
    Buloxibutid (Standard) 477775-14-7
    Buloxibutid (AT2 receptor agonist C21) (Standard) is the analytical standard of Buloxibutid (HY-100113). This product is intended for research and analytical applications. Buloxibutid is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis.
    Buloxibutid (Standard)
  • HY-100115R
    TA-02 (Standard) 1784751-19-4 98%
    TA-02 (Standard) is the analytical standard of TA-02 (HY-100115). This product is intended for research and analytical applications. TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).
    TA-02 (Standard)
  • HY-10011BR
    (Rac)-SCH 563705 (Standard) 2701435-64-3 98%
    (Rac)-SCH 563705 (Standard) is the analytical standard of (Rac)-SCH 563705 (HY-10011B). This product is intended for research and analytical applications. (Rac)-SCH 563705 is a racemic mixture of SCH 563705 (HY-10011). SCH 563705 (compound 16) is a potent and orally active CXCR2 and CXCR1 antagonist with IC50 values ​​of 1.3 nM and 7.3 nM and Ki values ​​of 1 nM and 3 nM, respectively.
    (Rac)-SCH 563705 (Standard)
  • HY-100125A
    Timegadine hydrochloride 71080-06-3 98%
    Timegadine hydrochloride (SR1368 hydrochloride) is the hydrochloride salt form of Timegadine (HY-100125). Timegadine hydrochloride is an orally active inhibitor for COX and lipo-oxygenase, that inhibits COX in washed rabbit platelets and rat brain with IC50 of 5 nM and 20 μM, inhibits lipo-oxygenase in in horse and washed rabbit platelets with IC50 of 100 μM. Timegadine hydrochloride exhibits anti-arthritis activity.
    Timegadine hydrochloride
  • HY-100131R
    GSK481 (Standard) 1622849-58-4 98%
    GSK481 (Standard) is the analytical standard of GSK481 (HY-100131). This product is intended for research and analytical applications. GSK481 is a highly potent, selective, and specific receptor interacting protein 1 (RIP1) kinase inhibitor with an IC50 of 1.3 nM, which inhibits Ser166 phosphorylation in wild-type human RIP1 (IC50=2.8 nM). GSK481 also exhibits excellent translation in the U937 cellular assay with an IC50 of 10 nM.
    GSK481 (Standard)
  • HY-100164R
    SDZ-MKS 492 (Standard) 114606-56-3 98%
    SDZ-MKS 492 (Standard) is the analytical standard of SDZ-MKS 492 (HY-100164). This product is intended for research and analytical applications. SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats.
    SDZ-MKS 492 (Standard)
  • HY-100176R
    PF-4878691 (Standard) 532959-63-0 98%
    PF-4878691 (Standard) is the analytical standard of PF-4878691. This product is intended for research and analytical applications. PF-4878691 (3M-852A) is an orally active TLR7 agonist. PF-4878691 has the innate immune response activity, antiviral efficacy against HCV, and can be used for the research of cancer.
    PF-4878691 (Standard)
  • HY-100183R
    GSK2239633A (Standard) 1240516-71-5 98%
    GSK2239633A (Standard) is the analytical standard of GSK2239633A (HY-100183). This product is intended for research and analytical applications. GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96.
    GSK2239633A (Standard)
  • HY-10019AR
    Varenicline dihydrochloride (Standard) 866823-63-4 98%
    Varenicline (dihydrochloride) (Standard) is the analytical standard of Varenicline (dihydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline dihydrochloride (Standard)
  • HY-10019S2
    Varenicline-13C15N 2140265-12-7 98%
    Varenicline-13C15N (CP 526555-13C15N) is 13C and 15N labeled Varenicline. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline-13C15N
  • HY-100223R
    Calpeptin (Standard) 117591-20-5
    Calpeptin (Standard) is the analytical standard of Calpeptin. This product is intended for research and analytical applications. Calpeptin is a potent, cell penetrating calpain inhibitor, with an ID50 of 40 nM for Calpain I in human platelets. Calpeptin is also an inhibitor of cathepsin K.
    Calpeptin (Standard)
  • HY-100233R
    IQ-1S free acid (Standard) 23146-22-7 98%
    IQ-1S (free acid) (Standard) is the analytical standard of IQ-1S (free acid) (HY-100233). This product is intended for research and analytical applications. IQ-1S free acid is a prospective inhibitor of NF-κB/activating protein 1 (AP-1) activity with an IC50 of 2.3±0.41 μM. IQ-1S free acid has binding affinity (Kd values) in the nanomolar range for all three JNKs with Kds of 100 nM, 240 nM, and 360 nM for JNK3, JNK1, and JNK2, respectively.
    IQ-1S free acid (Standard)
  • HY-100256R
    Trifarotene (Standard) 895542-09-3 98%
    Trifarotene (Standard) is the analytical standard of Trifarotene. This product is intended for research and analytical applications. Trifarotene (CD5789) is a potent and selective RARγ agonist. Trifarotene (CD5789) shows ∼65-fold and ∼16-fold selectivitiy for the RARγ (EC50=7.7 nM) over RARα (EC50=500 nM) and RARβ (EC50=125 nM), respectively.
    Trifarotene (Standard)
  • HY-100302R
    FR183998 free base (Standard) 239440-20-1
    FR183998 free base (Standard) is the analytical standard of FR183998 free base (HY-100302). This product is intended for research and analytical applications. FR183998 free base is a potent Na+/H+-exchange inhibitor, with IC50s of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pHi change in rat lymphocytes, rat and human platelets, respectively.
    FR183998 free base (Standard)
  • HY-100365R
    Remetinostat (Standard) 946150-57-8 98%
    Remetinostat (Standard) is the analytical standard of Remetinostat (HY-100365). This product is intended for research and analytical applications. Remetinostat (SHP-141) is a hydroxamic acid-based histone deacetylase (HDAC) inhibitor. Remetinostat alleviates Imiquimod (HY-B0180)-induced psoriatic dermatitis. Remetinostat can be used for study of cutaneous T-cell lymphoma.
    Remetinostat (Standard)
  • HY-100375R
    Diroximel fumarate (Standard) 1577222-14-0
    Diroximel fumarate (Standard) is the analytical standard of Diroximel fumarate (HY-100375). This product is intended for research and analytical applications. Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF). Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS). Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity.
    Diroximel fumarate (Standard)
  • HY-100432R
    LOC14 (Standard) 877963-94-5 98%
    LOC14 (Standard) is the analytical standard of LOC14 (HY-100432). This product is intended for research and analytical applications. LOC14 is a potent Protein disulfide isomerase (PDI) inhibitor with EC50 and Kd values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding. LOC14 inhibits PDIA3 activity, decreases intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in lung epithelial cells.
    LOC14 (Standard)
  • HY-100438R
    Hydronidone (Standard) 851518-71-3 98%
    Hydronidone (Standard) is the analytical standard of Hydronidone (HY-100438). This product is intended for research and analytical applications. Hydronidone is an orally active pyridine derivative. Hydronidone is an inhibitor of phosphodiesterase-4 (PDE4) and cyclo-oxygenase (COX) as well as TGF-β. Hydronidone induces mitochondrial dysfunction and triggers apoptosis. Hydronidone can be used for liver fibrosis, anti-inflammation and anti-cancer study.
    Hydronidone (Standard)
  • HY-100441R
    Treprostinil (Standard) 81846-19-7 98%
    Treprostinil (Standard) is the analytical standard of Treprostinil. This product is intended for research and analytical applications. Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.
    Treprostinil (Standard)
Cat. No. Product Name / Synonyms Application Reactivity